엔리벡스 테라퓨틱스(ENLV)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.80 (+9.69%), 시가총액 $0.17B, PER (주가수익비율) 0.03, 52주 최저~최고 $0.67 ~ $1.82.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in
엔리벡스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
엔리벡스 테라퓨틱스의 현재 주가는 $0.80 (+9.69%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
엔리벡스 테라퓨틱스의 시가총액은 약 $0.17B입니다. PER은 0.03입니다.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophag